In a new study entitled “Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease” an international team of scientists discovered that anti-malaria drugs chloroquine and amodiaquine are potential therapeutics for Parkinson’s disease. The study was published in…
News
Symptoms associated with Parkinson’s disease include tremor, muscle stiffness, and slowed movement that make it difficult to execute such simple tasks as holding an eating utensil steady, and patients currently have few options for relief outside of a hospital or clinic. Some medications can help, but over time they tend…
Geneticist Haydeh Payami, PhD., has made it her life’s mission to prevent parkinson’s disease (PD) in individuals who are genetically prone to the debilitating condition, and to devise effective personalized treatments for people who already have the disease. To achieve these lofty goals, Dr. Payami, who earned a PhD…
Deciphering the complex connections and neural networks of the brain is a herculean task. The brain is made of grey and white matter – the former consisting of neuronal cell bodies associated with receipt of sensory information from all major organs of the body aiding in vital processes like muscle…
Plans for a new research venture is in the works in the North-West of England through the joint efforts of the Association for the Independence of Disabled People (AID) and medical researchers at Lancaster University. AID was founded by Mr. Paul and the Hon. Mrs. Ruth Adorian of Windermere, following Ruth’s own…
In a new study entitled “Dopaminergic Modulation of Decision Making and Subjective Well-Being”, published in the Journal of Neuroscience, researchers show that decisions on risk-taking may be influenced by a boost in the levels of the neurotransmitter dopamine. These findings are in line with previous reports that…
Progressive loss of neurons in the brains of Parkinson’s patients is a slow yet inexorable process, and so far, there are no drugs that can halt this insidious process. However, teams of researchers at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have now…
Researchers at the University of Alabama at Birmingham (UAB) and Pfizer Inc. recently reported encouraging findings on a new inhibitor drug that can reduce neurodegeneration in animal models of Parkinson’s disease. The study was published in The Journal of Biological Chemistry and is entitled “…
Rehovot, Israel based Pharma Two B Ltd. is reportedly mulling issuance of an IPO after announcing successful results in the company’s Phase IIb pivotal study of P2B001 for treatment of early stage Parkinson’s Disease (PD) which is boosting the company’s confidence in taking its quest for financing to…
Many late-stage Parkinson’s disease patients have a high risk of suffering dangerous, sometimes fatal, falls. A major reason for increased propensity for falling is the disabling Parkinson’s symptom referred to as “Freezing of Gait” (FoG) — brief episodes of inability to step forward typically occurring during initiation of a step or…
Recent Posts
- It turned out Uncle Brandon didn’t need a cheerleader
- Parkinson’s advocates push for urgency as national plan begins
- ‘Unexpected’ study results find no toxic protein clumps in Parkinson’s patients
- Review spotlights gut bacteria as possible Parkinson’s treatment target
- With new FDA green light for developer, Parkinson’s clinical trial to launch soon